Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jihyun | - |
dc.contributor.author | Kim, June Hyuk | - |
dc.contributor.author | Kang, Hyun Guy | - |
dc.contributor.author | Park, Seog Yun | - |
dc.contributor.author | Yu, Jung Yeon | - |
dc.contributor.author | Lee, Eun Young | - |
dc.contributor.author | Oh, Sung Eun | - |
dc.contributor.author | Yun, Tak | - |
dc.contributor.author | Park, Charny | - |
dc.contributor.author | Cho, Soo Young | - |
dc.contributor.author | You, Hye Jin | - |
dc.date.accessioned | 2023-08-16T08:32:34Z | - |
dc.date.available | 2023-08-16T08:32:34Z | - |
dc.date.issued | 2018-12 | - |
dc.identifier.issn | 1471-2350 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/114381 | - |
dc.description.abstract | Background: Several studies have investigated the molecular drivers and therapeutic targets in adult soft tissue sarcomas. However, such studies are limited by the genomic heterogeneity and rarity of sarcomas, particularly in those with complex and unbalanced karyotypes. Additional biomarkers are needed across sarcoma types to improve therapeutic strategies. To investigate the molecular characteristics of complex karyotype sarcomas (CKSs) for therapeutic targets, we performed genomic profiling. Results: The mutational landscape showed that TP53, ATRX, and PTEN genes were highly mutated. CKS samples were categorized into three groups based on copy number variations that were associated with CDK4 and RB1 signatures. Integrated analysis of genomic and transcriptomic data revealed several pathways related to PDGFR, which could be a strategic target for anti-sarcoma therapy. Conclusions: This study provides a detailed molecular classification of CKSs and proposes several therapeutic targets. Targeted or combinational therapies for treating CKS should be considered before chemotherapy. © 2018 The Author(s). | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BioMed Central | - |
dc.title | Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1186/s12881-018-0722-6 | - |
dc.identifier.scopusid | 2-s2.0-85059286783 | - |
dc.identifier.wosid | 000454633400001 | - |
dc.identifier.bibliographicCitation | BMC Medical Genetics, v.19, pp 1 - 11 | - |
dc.citation.title | BMC Medical Genetics | - |
dc.citation.volume | 19 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 11 | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Genetics & Heredity | - |
dc.relation.journalWebOfScienceCategory | Genetics & Heredity | - |
dc.subject.keywordPlus | MICROSATELLITE INSTABILITY | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | TUMOR | - |
dc.subject.keywordPlus | CLASSIFICATION | - |
dc.subject.keywordPlus | AMPLIFICATION | - |
dc.subject.keywordPlus | ENCYCLOPEDIA | - |
dc.subject.keywordPlus | GENES | - |
dc.subject.keywordAuthor | CDK4 and RB1 | - |
dc.subject.keywordAuthor | Complex karyotype sarcoma | - |
dc.subject.keywordAuthor | Molecular characterization | - |
dc.subject.keywordAuthor | PDGFRA | - |
dc.identifier.url | https://link.springer.com/article/10.1186/s12881-018-0722-6?utm_source=getftr&utm_medium=getftr&utm_campaign=getftr_pilot | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.